True top-performing growth shares are incredibly difficult to find, and maximising portfolio returns often takes significant research and a dose of luck – so here's 3 top long-term buys in the S&P/ASX 200 (INDEXASX: XJO) index that could make you a millionaire.
The Appen share price has more than doubled in 2019 alone and has continued its stratospheric rise since its IPO in 2015.
Appen is currently trading at $28.18 per share or 71.8x earnings, which while lofty, is certainly not the most expensive of the ASX growth stocks on the market.
The company posted strong earnings before interest, tax, depreciation and amortisation (EBITDA) of $71.3 million and largely driven by demand for natural language and speech processing capabilities.
Appen's business model has continued to capitalise on the global appetite for enhanced artificial intelligence (AI) and machine learning capabilities with strong margin and volume growth seen in its February 2019 results.
Given the stock is up nearly 4400% since its IPO, I think there's further potential to be a millionaire-maker at its current $25.90 valuation as it shapes up as the "Afterpay of 2019".
-
Breville Group Ltd (ASX BRG)
The Breville Group share price has climbed 61.3% higher to $16.82 per share so far this year, as the company posted strong half-year earnings in February 2019.
The homewares and appliance maker saw strong growth in key operating segments across Europe and the United States, citing the explosion of a healthy juice craze as a key contributor to earnings.
While a craze by its very nature is unlikely to be sustained, I think Breville remains a top ASX stock in the consumer discretionary sector that could benefit if we remain at the top of the business cycle for a little while longer.
With a market cap of $2.2 billion and trading at 36.4x earnings, I think the Breville share price has more room to grow in 2019 and beyond, which is why it made my ABC of millionaire-makers for the second half of 2019.
-
Cochlear Ltd (ASX: COH)
While the Cochlear share price has only climbed 19.4% higher in 2019, I think this one remains a strong long-term growth option in the healthcare sector.
At $208.86 per share, Cochlear may not be an ideal option for those looking to invest the $500 minimum on the ASX in an un-diversified portfolio. However, I think the long-term prospects for the health technology company remain strong and the growth in both access to and funding for disability services bode well for the long-term technical environment for Cochlear.
The company is on the pricier side at 46.1x earnings, but I believe that if it can capitalise on its recently announced Nucleus® ProfileTM Plus Series cochlear implant, which was designed for routine 1.5 and 3 Tesla magnetic resonance imaging scans without the need to remove the internal magnet.
The potential market growth remains strong and Cochlear as the incumbent is best placed to expand its revenue streams, making it a great option round-out the ABC of millionaire-makers.
